TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i>-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
Line Schmidt Tarpgaard(Odense University Hospital), José M.A. Moreira(Technical University of Denmark)
Cited by 9
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses
|BMC Cancer|2003|143